| Name | Title | Contact Details |
|---|---|---|
Anthony Rossomando |
Chief Technology Officer | Profile |
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Noninvasive monitoring that enables less invasive care. My care setting is: MORE Noninvasive monitoring that enables less invasive care. My care setting is: MORE
Privée Clinics is a state-of-the-art facility that utilizes the latest and most innovative cutting edge technology in the industry of mental and physical
Titan Pharmaceuticals, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fusion MD Network is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.